University of Dundee

Case Studies

  • Since 2001, 27 new drugs that target kinases have been approved for clinical use with current sales of US$30 billion. The development of these drugs depended on the kinase profiling methods developed by the University of Dundee. By harnessing this world-class research in a unique collaboration between the University and world leading pharmaceutical companies, the entrepreneurial vision of Sir Philip Cohen maximised the translation of signalling research in Dundee towards clinical benefit.

  • Pioneering automated drug design methodologies developed by researchers at the University of Dundee led to the spin out of ex scientia Ltd in 2012. The company provides technologies to enhance the efficacy and the efficiency of drug discovery for the pharmaceutical industry.

  • University of Dundee spinout company Dundee Cell Products provides life-sciences technology and reagents to the academic research community and biotech involved in the discovery and development of new drugs.

  • Thanks to work carried out by researchers at the University of Dundee, patients affected by inherited keratin skin disorders can now obtain a definitive diagnosis through the provision of genetic testing, which has been pivotal in enabling accurate treatment of these disorders and driving the development of targeted therapeutics.

  • The Drug Discovery Unit at the University of Dundee is developing new treatments for unmet medical need. The DDU bridges the gap between academic scientific research and commercial drug discovery and development.

  • Scientists at the University of Dundee applied their knowledge to inform worldwide governmental and regulatory policy on cyanotoxins, among the most hazardous natural poisons in the aquatic environment.

  • A key regulator of cell growth and survival called PKB (also called AKT) is the focus of numerous anti-cancer drug clinical trials. The role of this protein and how it is switched on was uncovered by researchers in Dundee and has stimulated pharmaceutical companies to undertake drug development campaigns focused on PKB as a target molecule. Moreover, this research led several life sciences companies to generate research tools to accelerate academic and industry research in this area.

  • Collaborative research carried out at the University of Dundee has suggested that the diabetes drug metformin may reduce the incidence of cancer. This has led to worldwide investigations into the use of metformin as a cancer preventative measure and the development of new drugs mirroring the effect of metformin.

  • Led in Dundee by Prof. Jason Swedlow FRSE, the Open Microscopy Environment is an international consortium has revolutionised the ability of researchers and industrial partners to handle, analyse, share and interpret vast amounts of image data.